Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Date:5/6/2008

er Conference. The

final efficacy results confirmed previously announced interim

results showing a survival benefit in patients with recurrent SCLC

who failed prior platinum-containing first-line chemotherapy or who

progressed within six months of first-line therapy. The median

overall survival in the picoplatin Phase 2 trial was 27 weeks for

refractory and resistant small cell lung cancer patients, a

population for which there is no approved therapy in the US. The

Pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse)

trial of intravenous picoplatin in SCLC is ongoing and compares

picoplatin with best supportive care to best supportive care alone.

The published median overall survival for best supportive care is 13

weeks for the platinum refractory and resistant patient group. Our

registrational trial is currently being conducted under a Special

Protocol Assessment from the U.S. Food and Drug Administration and

is evaluating overall survival as the primary endpoint. Top-line

Phase 3 data is targeted for mid-2009.

* Colorectal Cancer: In January, we presented preliminary safety data

from our 50-patient Phase 1 dose-escalation study of picoplatin in

patients with metastatic colorectal cancer at the ASCO

Gastrointestinal Cancers Symposium. Picoplatin was shown to have

manageable toxicity in combination with 5-fluorouracil and

leucovorin. Picoplatin did not cause severe neurotoxicity (Grade 3

or higher), as is commonly seen in metastatic CRC patients treated

with oxaliplatin as part of the FOLFOX regimen. Current National

Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in

Oncology for colon cancer encourage the discontinuation of FOLFO
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... (PRWEB) May 21, 2015 uBiome, ... announced a partnership with PicnicHealth, a healthcare company ... Participants diagnosed with Inflammatory Bowel Disease (IBD) will ... a complementary uBiome research kit. Both companies were ... , For more information on this ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Patent Offering, ... method for diagnostic or therapeutic imaging within a body ... uses an endoscope having a low cost, single-use disposable ... filing date was October 18, 2013 and the patent ... technology enables the physician to customize the lighting and ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... upcoming poster presentation at the International Society for ... for chronic Achilles tendinosis currently in a Phase ... May 29 th from 5:30 PM to ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has announced ... Insights" report to their offering. Technical ... the Health and Wellness sector and has identified top ... in the year 2015. The research service provides an ... wellness technologies that are anticipated to have the highest ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Top Technologies in the Health and Wellness Industry 2015 2
... to Pursue All Pharmaceutical and Health-Oriented Nutraceutical Uses of ... Spherix Incorporated (Nasdaq: SPEX ), an innovator ... technical and regulatory consulting services to food, supplement, biotechnology ... the 1996 license agreement pursuant to which it granted ...
... ... of GxP process and document management software solutions for life science ... electronic regulatory submission solutions for the life sciences industry, today announced ... Annual Meeting. GxP2eCTD is a bundled solution of MasterControl document ...
... CHARLOTTESVILLE, Virginia, June 23 ... targeting epilepsy, has shown,positive results in the Kainic ... existing drug that Biovista repositioned in epilepsy, exhibits,both ... induced a statistically significant decrease of epileptic activity ...
Cached Biology Technology:Spherix Announces Termination of Arla License Agreement 2Spherix Announces Termination of Arla License Agreement 3Spherix Announces Termination of Arla License Agreement 4MasterControl and Datafarm Launch GxP2eCTD at the DIA 45th Annual Meeting 2MasterControl and Datafarm Launch GxP2eCTD at the DIA 45th Annual Meeting 3MasterControl and Datafarm Launch GxP2eCTD at the DIA 45th Annual Meeting 4Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy 2
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... (Santa Barbara, Calif.) Remarkable progress in ... team of leading scientists, directed by experts at UC Santa Barbara. ... Cell . Stem cell biology is making waves around the ... the body. While many scientists see these breakthroughs as viable, there ...
... at the Virginia Bioinformatics Institute at Virginia Tech ... hormone with known beneficial properties for the treatment ... http://www.ncbi.nlm.nih.gov/pubmed/210882970 ), which are published in the November ... important new drug targets for the development of ...
... cholera appear to have evolved a distinctly different mechanism to ... current issue of the online journal mBio . ... diarrheal disease cholera. While there are more than 200 ... been known to cause epidemic and pandemic outbreaks of disease, ...
Cached Biology News:National team of scientists peers into the future of stem cell biology 2National team of scientists peers into the future of stem cell biology 3National team of scientists peers into the future of stem cell biology 4Researchers discover how natural drug fights inflammation 2Researchers discover how natural drug fights inflammation 3
... Forma's stainless steel rack ... adjustable mechanism that permits ... shaking angles, and "snap-in" ... universal rack holder will ...
... 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat inactivation ... Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM KCl, ... BSA, 50% glycerol. Shipping and Storage: Shipped on ... unit is defined as the amount of enzyme ...
... stainless-steel shaker flask clips, purpose-designed to firmly ... All clips are equipped with a top ... include a bottom retainer spring, and silicon ... expensive glassware. Clips include the required ...
ANTI DIPHTH TOX A SU...
Biology Products: